Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 6/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | GYS1 | P13807 | 2/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16758023 | 1.00 | PDK2 (0.42) | PDK2SPHK2SPHK1CNR2CYP4F2 | |
| SCHEMBL15537981 | 0.93 | PDK2 (0.44) | PDK2SPHK2SPHK1CNR2CYP4F2 | |
| SCHEMBL18842763 | 0.93 | PDK2 (0.42) | PDK2SPHK2SPHK1CNR2CYP4F2 | |
| SCHEMBL15537984 | 0.93 | PDK2 (0.44) | PDK2SPHK2SPHK1CNR2CYP4F2 | |
| SCHEMBL18848900 | 0.90 | PDK2 (0.41) | PDK2CNR2CYP4F2CYP4A11GPR119 | |
| SCHEMBL16758060 | 0.89 | CNR2 (0.39) | PDK2CNR2CYP4F2CYP4A11GPR119 | |
| SCHEMBL16758055 | 0.89 | CNR2 (0.39) | PDK2CNR2CYP4F2CYP4A11GPR119 | |
| SCHEMBL16758038 | 0.87 | PDK2 (0.43) | PDK2SPHK2SPHK1CNR2CYP4F2 | |
| SCHEMBL21043237 | 0.87 | GPR119 (0.35) | PDK2CYP4F2CYP4A11GPR119 | |
| SCHEMBL16758040 | 0.87 | PDK2 (0.43) | PDK2SPHK2SPHK1CNR2CYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3074384-B1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-05-22 | — | — | EP | claimed |
| US-9776987-B2 | Amide derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-10-03 | — | — | US | claimed |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-11 | — | — | US | claimed |
| EP-3074384-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-10-05 | — | — | EP | claimed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | claimed |
| EP-3074384-B1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-05-22 | — | — | EP | disclosed |
| US-9776987-B2 | Amide derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-10-03 | — | — | US | disclosed |
| US-9776987-B2 | Amide derivatives for GPR119 agonist | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2017-10-03 | — | — | US | disclosed |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-11 | — | — | US | disclosed |
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-05-11 | — | — | US | disclosed |
| EP-3074384-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2016-10-05 | — | — | EP | disclosed |
| WO-2015080446-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129875-A1 | AMIDE DERIVATIVES FOR GPR119 AGONIST | GPR119, FFAR2, GLP1R | PDK2 1354/4885SPHK2 587/4885SPHK1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.